
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9286081/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy. Autoimmunity Reviews, 2020, 19, 102568.	2.5	637
2	Two Xâ€linked agammaglobulinemia patients develop pneumonia as COVIDâ€19 manifestation but recover. Pediatric Allergy and Immunology, 2020, 31, 565-569.	1.1	298
3	Steroidâ€Responsive Encephalitis in Coronavirus Disease 2019. Annals of Neurology, 2020, 88, 423-427.	2.8	230
4	Management of Patients on Dialysis and With Kidney Transplantation During the SARS-CoV-2 (COVID-19) Pandemic in Brescia, Italy. Kidney International Reports, 2020, 5, 580-585.	0.4	195
5	Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Encephalitis Is a Cytokine Release Syndrome: Evidences From Cerebrospinal Fluid Analyses. Clinical Infectious Diseases, 2021, 73, e3019-e3026.	2.9	131
6	Clinical presentation and initial management critically ill patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in Brescia, Italy. Journal of Critical Care, 2020, 58, 29-33.	1.0	130
7	The increasing burden and complexity of multi-morbidity and polypharmacy in geriatric HIV patients: a cross sectional study of people aged 65 – 74 years and more than 75 years. BMC Geriatrics, 2018, 18, 99.	1.1	117
8	Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial. Journal of Translational Medicine, 2020, 18, 405.	1.8	98
9	Clinical Presentation and Outcomes of Severe Acute Respiratory Syndrome Coronavirus 2–Related Encephalitis: The ENCOVID Multicenter Study. Journal of Infectious Diseases, 2021, 223, 28-37.	1.9	87
10	Evaluation of Liver Fibrosis: Concordance Analysis between Noninvasive Scores (APRI and FIB-4) Evolution and Predictors in a Cohort of HIV-Infected Patients without Hepatitis C and B Infection. Clinical Infectious Diseases, 2011, 52, 1164-1173.	2.9	70
11	Treatment simplification to atazanavir/ritonavir + lamivudine versus maintenance of atazanavir/ritonavir + two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M). Journal of Antimicrobial Chemotherapy, 2017, 72, dkw557.	1.3	62
12	High prevalence of radiological vertebral fractures in HIV-infected males. Endocrine, 2012, 41, 512-517.	1.1	52
13	Survival in HIV-Infected Patients after a Cancer Diagnosis in the cART Era: Results of an Italian Multicenter Study. PLoS ONE, 2014, 9, e94768.	1.1	50
14	The presence of anti-Tat antibodies in HIV-infected individuals is associated with containment of CD4+T-cell decay and viral load, and with delay of disease progression: results of a 3-year cohort study. Retrovirology, 2014, 11, 49.	0.9	48
15	Vitamin D deficiency in HIV infection: an underestimated and undertreated epidemic. European Review for Medical and Pharmacological Sciences, 2013, 17, 1218-32.	0.5	43
16	A Randomized, Pilot Trial to Evaluate Glomerular Filtration Rate by Creatinine or Cystatin C in Naive HIV-Infected Patients After Tenofovir/Emtricitabine in Combination With Atazanavir/Ritonavir or Efavirenz. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 59, 18-24.	0.9	37
17	Risk of Severe Non AIDS Events Is Increased among Patients Unable to Increase their CD4+ T-Cell Counts >200+/μI Despite Effective HAART. PLoS ONE, 2015, 10, e0124741.	1.1	36
18	Six cases of sepsis caused by Pantoea agglomerans in a teaching hospital. New Microbiologica, 2009, 32, 119-23.	0.1	36

#	Article	IF	CITATIONS
19	Asymptomatic neurocognitive disorders in patients infected by HIV: fact or fiction?. BMC Medicine, 2011, 9, 138.	2.3	35
20	Maraviroc as Intensification Strategy in HIV-1 Positive Patients with Deficient Immunological Response: an Italian Randomized Clinical Trial. PLoS ONE, 2013, 8, e80157.	1.1	35
21	Malaria Prophylaxis: A Comprehensive Review. Pharmaceuticals, 2010, 3, 3212-3239.	1.7	33
22	Prospective evaluation of bone markers, parathormone and 1,25-(OH)2 vitamin D in HIV-positive patients after the initiation of tenofovir/emtricitabine with atazanavir/ritonavir or efavirenz. BMC Infectious Diseases, 2012, 12, 38.	1.3	33
23	Incidence of cardiovascular events in HIV-positive patients compared to general population over the last decade: a population-based study from 2000 to 2012. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2016, 28, 1551-1558.	0.6	30
24	Antiretroviral therapy in geriatric HIV patients: the GEPPO cohort study. Journal of Antimicrobial Chemotherapy, 2017, 72, 2879-2886.	1.3	30
25	Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial. Journal of Antimicrobial Chemotherapy, 2018, 73, 1955-1964.	1.3	29
26	Kidney disease in HIV-infected patients. European Review for Medical and Pharmacological Sciences, 2013, 17, 2660-7.	0.5	29
27	Phenotypic and genotypic evaluation of slime production by conventional and molecular microbiological techniques. Microbiological Research, 2009, 164, 522-528.	2.5	24
28	Increase in Standard Cholesterol and Large HDL Particle Subclasses in Antiretroviral-NaÃ <sup>-</sup> ve Patients Prescribed Efavirenz Compared to Atazanavir/Ritonavir. HIV Clinical Trials, 2012, 13, 245-255.	2.0	24
29	Screening for Neurocognitive Impairment in HIV-Infected Individuals at First Contact after HIV Diagnosis: The Experience of a Large Clinical Center in Northern Italy. International Journal of Molecular Sciences, 2016, 17, 434.	1.8	24
30	Synthetic HIV-1 matrix protein p17-based AT20-KLH therapeutic immunization in HIV-1-infected patients receiving antiretroviral treatment: A phase I safety and immunogenicity study. Vaccine, 2014, 32, 1072-1078.	1.7	23
31	Development and validation of SCOPE score: A clinical score to predict COVID-19 pneumonia progression to severe respiratory failure. Cell Reports Medicine, 2022, 3, 100560.	3.3	23
32	Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART. Journal of Antimicrobial Chemotherapy, 2016, 71, 1056-1062.	1.3	22
33	OUP accepted manuscript. Journal of Antimicrobial Chemotherapy, 2018, 73, 177-182.	1.3	22
34	Cerebrospinal fluid HIV-1 escape according to different thresholds and underlying comorbidities. Aids, 2019, 33, 759-762.	1.0	19
35	Dolutegravir is not associated with weight gain in antiretroviral therapy experienced geriatric patients living with HIV. Aids, 2021, 35, 939-945.	1.0	19
36	A 2021 Update on Syphilis: Taking Stock from Pathogenesis to Vaccines. Pathogens, 2021, 10, 1364.	1.2	19

#	Article	IF	CITATIONS
37	Comparison between the gold standard DXA with calcaneal quantitative ultrasound based-strategy (QUS) to detect osteoporosis in an HIV infected cohort. Brazilian Journal of Infectious Diseases, 2017, 21, 581-586.	0.3	18
38	Role of bone mineral density in predicting morphometric vertebral fractures in patients with HIV infection. Osteoporosis International, 2014, 25, 2263-2269.	1.3	17
39	Liver fibrosis progression and clinical outcomes are intertwined. Medicine (United States), 2016, 95, e4091.	0.4	17
40	Omicron BA.2 Lineage, the "Stealth―Variant: Is It Truly a Silent Epidemic? A Literature Review. International Journal of Molecular Sciences, 2022, 23, 7315.	1.8	17
41	Unboosted Atazanavir for Treatment of HIV Infection. Drugs, 2012, 72, 1161-1173.	4.9	16
42	Clinical and immunological outcomes according to adherence to first-line HAART in a urban and rural cohort of HIV-infected patients in Burkina Faso, West Africa. BMC Infectious Diseases, 2014, 14, 153.	1.3	16
43	Low-level viraemia, measured as viraemia copy-years, as a prognostic factor for medium–long-term all-cause mortality: a MASTER cohort study. Journal of Antimicrobial Chemotherapy, 2016, 71, 3519-3527.	1.3	16
44	Serological Response to SARS-CoV-2 in Health Care Workers Employed in a Large Tertiary Hospital in Lombardy, Northern Italy. Microorganisms, 2021, 9, 488.	1.6	16
45	Enhanced Immunological Recovery With Early Start of Antiretroviral Therapy During Acute or Early HIV Infection–Results of Italian Network of ACuTe HIV InfectiON (INACTION) Retrospective Study. Pathogens and Immunity, 2020, 5, 8.	1.4	16
46	Cohort Profile: Standardized Management of Antiretroviral Therapy Cohort (MASTER Cohort). International Journal of Epidemiology, 2017, 46, dyv192.	0.9	15
47	DISSEMINATED HISTOPLASMOSIS AS AIDS PRESENTATION. CASE REPORT AND COMPREHENSIVE REVIEW OF CURRENT LITERATURE. Mediterranean Journal of Hematology and Infectious Diseases, 2017, 10, e2018040.	0.5	15
48	Prevalence of Integrase Strand Transfer Inhibitors Resistance Mutations in Integrase Strand Transfer Inhibitors-Naive and -Experienced HIV-1 Infected Patients: A Single Center Experience. AIDS Research and Human Retroviruses, 2018, 34, 570-574.	0.5	15
49	Neutrophil to Lymphocyte Ratio and Cardiovascular Disease Incidence in HIV-Infected Patients: A Population-Based Cohort Study. PLoS ONE, 2016, 11, e0154900.	1.1	14
50	Switching from efavirenz to rilpivirine improves sleep quality and self-perceived cognition but has no impact on neurocognitive performances. Aids, 2020, 34, 53-61.	1.0	14
51	MALARIA AND HIV IN ADULTS: When The Parasite runs into The Virus. Mediterranean Journal of Hematology and Infectious Diseases, 2012, 4, e2012032.	0.5	12
52	Perinatally HIV-Infected Youths After Transition from Pediatric to Adult Care, a Single-Center Experience from Northern Italy. AIDS Research and Human Retroviruses, 2018, 34, 241-243.	0.5	12
53	Circulating angiopoietin-like protein 2 levels are associated with decreased renal function in HIV subjects on cART: A potential marker of kidney disease. Biomedical Reports, 2019, 10, 140-144.	0.9	12
54	Virological effectiveness and CD4+ T-cell increase over early and late courses in HIV infected patients on antiretroviral therapy: focus on HCV and anchor class received. AIDS Research and Therapy, 2012, 9, 18.	0.7	11

#	Article	IF	CITATIONS
55	Survival in <scp>HIV</scp> â€infected patients with lymphoma according to the choice of antiretroviral treatment: an observational multicentre study. HIV Medicine, 2018, 19, 523-531.	1.0	11
56	A prospective randomized trial on abacavir/lamivudine plus darunavir/ritonavir or raltegravir in HIV-positive drug-naìve patients with CD4<200 cells/uL (the PRADAR study). PLoS ONE, 2019, 14, e0222650.	1.1	11
57	Prevalence of Non-B HIV-1 Subtypes in North Italy and Analysis of Transmission Clusters Based on Sequence Data Analysis. Microorganisms, 2020, 8, 36.	1.6	11
58	Disengagement and reengagement of HIV continuum of care in a single center cohort in northern Italy. HIV Research and Clinical Practice, 2019, 20, 1-11.	1.1	10
59	Decrease in New Diagnosis of HIV/AIDS in the Two Years Period 2019-2020: Impact of COVID-19 Pandemic. Journal of Public Health Research, 2022, 11, jphr.2021.2256.	0.5	10
60	P. falciparum malaria recrudescence in a cancer patient. Infezioni in Medicina, 2009, 17, 33-4.	0.7	10
61	Role of Normalized T-Cell Subsets in Predicting Comorbidities in a Large Cohort of Geriatric HIV-Infected Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 76, 338-342.	0.9	9
62	Elderly HIV-positive women: A gender-based analysis from the Multicenter Italian "GEPPO―Cohort. PLoS ONE, 2019, 14, e0222225.	1.1	9
63	Laboratory considerations amidst the coronavirus disease 2019Âoutbreak: the Spedali Civili in Brescia experience. Bioanalysis, 2020, 12, 1223-1230.	0.6	8
64	Host and disease factors are associated with cognitive function in European <scp>HIV</scp> â€infected adults prior to initiation of antiretroviral therapy. HIV Medicine, 2016, 17, 471-478.	1.0	7
65	Atazanavir intracellular concentrations remain stable during pregnancy in HIV-infected patients. Journal of Antimicrobial Chemotherapy, 2017, 72, 3163-3166.	1.3	6
66	Effectiveness of kidney transplantation in HIV-infected recipients under combination antiretroviral therapy: a single-cohort experience (Brescia, Northern Italy). Infection, 2018, 46, 77-82.	2.3	6
67	Predictors of incomplete viral response and virologic failure in patients with acute and early HIV infection. Results of Italian Network of ACuTe HIV InfectiON (INACTION) cohort. HIV Medicine, 2020, 21, 523-535.	1.0	6
68	Hypogonadism and liver fibrosis in HIV-infected patients. Journal of Endocrinological Investigation, 2021, 44, 1971-1979.	1.8	6
69	Mechanical Ventilation in COVID-19 Patients: Insights into the Role of Age and Frailty from a Multicentre Observational Study. , 2022, 13, 340.		6
70	Long-lasting humoral immune response induced in HIV-1-infected patients by a synthetic peptide (AT20) derived from the HIV-1 matrix protein p17 functional epitope. HIV Clinical Trials, 2015, 16, 157-162.	2.0	5
71	Patient-Reported Outcomes in an Observational Cohort of HIV-1-Infected Adults on Darunavir/Cobicistat-Based Regimens: Beyond Viral Suppression. Patient, 2020, 13, 375-387.	1.1	5
72	Impact of hypogonadism on bone mineral density and vertebral fractures in HIV-infected men. Journal of Endocrinological Investigation, 2022, 45, 433-443.	1.8	5

#	Article	IF	CITATIONS
73	Evaluation of Boosted and Unboosted Atazanavir Plasma Concentration in HIV Infected Patients. Current HIV Research, 2014, 11, 642-646.	0.2	5
74	Elderly Women With Human Immunodeficiency Virus Infection: Is There an Effect of the Virus on Neuropsychological Profile?. Journal of the American Geriatrics Society, 2014, 62, 194-196.	1.3	4
75	Leronlimab (PRO 140) in vitro activity against 4-class drug resistant HIV-1 from heavily treatment experienced subjects. Pharmacological Research, 2022, 176, 106064.	3.1	4
76	Monotherapy with darunavir/ritonavir or lopinavir/ritonavir versus standard antiretroviral therapy: a randomized clinical trial (2pm Study). New Microbiologica, 2016, 39, 290-294.	0.1	4
77	Cryptogenic Liver Diseases: Sailing by Sight from HIV Co-Infection with Hepatitis Viruses to HIV Mono-Infection Through the Pillars of Hercules. Current HIV Research, 2011, 9, 61-69.	0.2	3
78	Pharmacokinetic Changes during Pregnancy According to Genetic Variants: a Prospective Study in HIV-Infected Patients Receiving Atazanavir-Ritonavir. Antimicrobial Agents and Chemotherapy, 2018, 62,	1.4	3
79	SARS-CoV-2 invades the West. How to face a COVID-19 epidemic in Lombardy, Northern Italy?. Infezioni in Medicina, 2020, 28, 133-134.	0.7	3
80	Low-dose Lung Radiotherapy for COVID-19-related Pneumonia: Preliminary Results of the Italian Mono-institutional COLOR-19 Trial. In Vivo, 2022, 36, 1959-1965.	0.6	3
81	Viremia copy-years and risk of estimated glomerular filtration rate reduction in adults living with perinatal HIV infection. PLoS ONE, 2020, 15, e0240550.	1.1	2
82	UVA1 phototherapy as a treatment option for plaque psoriasis in HIVâ€positive patients. Photodermatology Photoimmunology and Photomedicine, 2020, 36, 478-480.	0.7	2
83	Psychological and Emotional Impact of COVID-19 Pandemic on People Living with Chronic Disease: HIV and Cancer. AIDS and Behavior, 2022, 26, 2920-2930.	1.4	2
84	Reply to van der Pas et al. Clinical Infectious Diseases, 2011, 53, 614-615.	2.9	1
85	Prognostic role of inflammatory biomarkers in HIVâ€infected patients with a first diagnosis of hepatocellular carcinoma: A singleâ€center study. Journal of Medical Virology, 2019, 91, 241-248.	2.5	1
86	Presence of V72I, G123S and R127K Integrase Inhibitor polymorphisms could reduce ART effectiveness: a retrospective longitudinal study. HIV Research and Clinical Practice, 2020, 21, 24-33.	1.1	1
87	Steroid-Responsive Encephalitis in Coronavirus Disease 2019. , 2020, 88, 423.		1
88	Non-B subtypes account for a large proportion of clustered primary HIV-1 infections in Italy. Sexually Transmitted Infections, 2022, , sextrans-2021-055289.	0.8	1
89	HIV-1 mutants expressing B cell clonogenic matrix protein p17 variants are increasing their prevalence worldwide. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	1
90	The Disagreement Among Methods to Evaluate Glomerular Filtration Rate in HIV-Infected Patients Naive to Antiretroviral Therapy. AIDS Research and Human Retroviruses, 2012, 28, 637-640.	0.5	0

#	Article	IF	CITATIONS
91	The good, the bad and the ugly: determinants of antiretroviral-associated toxicities. Future Virology, 2016, 11, 239-243.	0.9	0
92	Role of systemic inflammation scores for prediction of clinical outcomes in patients treated with atazanavir not boosted by ritonavir in the Italian MASTER cohort. BMC Infectious Diseases, 2017, 17, 212.	1.3	0
93	Impact of genotypic susceptibility score on cART outcomes during primary HIV infection. Journal of Medical Virology, 2019, 91, 1891-1895.	2.5	0
94	Descriptive modification of inflammatory markers in HIV patients after cART initiation according to gender, smoking habit, CMV infection, BMI and serum lipids. Cytokine, 2021, 143, 155547.	1.4	0
95	Durability of Integrase STrand Inhibitor (InSTI)-based regimen in geriatric people living with HIV in the GEPPO cohort. PLoS ONE, 2021, 16, e0258533.	1.1	0
96	Autologous Stem Cell Transplantation Is Effective in Chemosensitive HIV-Associated Lymphoma Irrespective of Previous Therapy and Histological Subtype. Blood, 2018, 132, 2145-2145.	0.6	0
97	Explorative study regarding influenza vaccine hesitancy among HIV-infected patients. Human Vaccines and Immunotherapeutics, 2022, 18, 1-7.	1.4	0
98	Title is missing!. , 2019, 14, e0222650.		0
99	Title is missing!. , 2019, 14, e0222650.		0
100	Title is missing!. , 2019, 14, e0222650.		0
101	Title is missing!. , 2019, 14, e0222650.		0